Several pan-PPAR agonists, including indeglitazar (EUCTR 2005-004227-19; NCT00425919), tetradecylthioacetic acid (NCT00605787), chiglitazar [74,75], and lanifibranor (NCT03459079) have been evaluated for T2DM. Here, PPARA is linked to type 2 diabetes mellitus.